Acute management of cancer-related hypercalcemia

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 507-513

  Chisholm, Marie A ^a,b   Mulloy, Anthony L ^b   Thomas Taylor, A ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; FUROSEMIDE; GALLIUM NITRATE; GLUCOCORTICOID; MITHRAMYCIN; SODIUM CHLORIDE;

CANCER; CLINICAL FEATURE; DIURESIS; DRUG EFFICACY; HYDRATION; HYPERCALCEMIA; PRIORITY JOURNAL; REVIEW;

EID: 0029986950     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000514     Document Type: Review

References (58)

1. Bajorunas DR. Disorders of endocrine function in the critically ill patients. In: Howland WS, Carlon GC, eds. Critical care of the cancer patient Chicago: Year Book Medical, 1985:143-72.
2. Warrell RP, Bockman RS. Metabolic emergencies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practices of oncology. Philadelphia: Lippincott,1989:1986-2000.
3. Ritch PS. Treatment of cancer-related hypercalcemia. Semin Oncol 1990;17(suppl 5):26-33.
4. Strewler GJ, Nissenson RA. Hypercalcemia in malignancy. West J Med 1990;153:635-40.
5. Hickey RC, Samaan NA, Jackson GL. Hypercalcemia in patients with breast cancer. Arch Surg 1981;116:545-52.
6. Mundy GR, Martin JT. The hypercalcemia of malignancy: pathogenesis and management Metabolism 1982;31:1247-77.
7. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma: a prospective study of 200 patients. Ann Intern Med 1974;80:205-8.
8. Warren MM, Utz DC, Kelalis PP. Concurrence of hypercephroma and hypercalcemia. Ann Surg 1971;174:863-5.
9. Mundy GR. Pathogenesis of hypercalcemia of malignancy. Clin Endocrinol 1985;23:705-14.
10. Mundy GR. Pathophysiology of cancer-associated hypercalcemia. Semin Oncol 1990,17(suppl 5):10-5.
11. Weinstein RS. Bone involvement in multiple myeloma. Am J Med 1992;93:591-4.
12. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD. Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res 1987;2:559-65.
13. Durie BGM, Salmon SE, Mundy GR. Relation of osteoclast activity factor production to extent of bone disease in multiple myeloma. Br J Haematol 1987;47:21-30.
14. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982;52:601-10.
15. Mundy GR. Calcium hemostasis: hypercalcaemia and hypocalcaemia. 2nd ed. London: Martin Dunitz, 1990:69-99.
16. Neilan B. Oncologic emergencies. Treating acute problems resulting from cancer and chemotherapy. Postgrad Med 1994;95:125-32.
17. Bajourunas DR. Clinical manifestations of cancer-related hypercalcemia. Semin Oncol 1990;17(suppl 5):16-25.
18. Fisken RA, Heath DA, Bold AM. Hypercalcemia: a hospital survey. Q J Med 1980;196:405-18.
19. Mundy GR, Raisz LG. Drugs for disorders of bone: pharmacological and clinical considerations. Drugs 1974;8:250-89.
20. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.
21. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992;326:1196-203.
22. Hall TG, Schaiff RA. Update on the medical treatment of hypercalcemia of malignancy. Clin Pharm 1993;12:117-25.
23. Stewart AF. Therapy of malignancy-associated hypercalcemia: 1983. Am J Med 1983;74:475-80.
24. Bilezikian JP. Clinical review 51: management of hypercalcemia. J Clin Endocrinol Metab 1993;77:1445-9.
25. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcemia. Q J Med 1981;50:473-81.
26. Schultz NJ. Body electrolyte homeostasis. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier Science Publishing, 1992:764-96.
27. Suki WN, Yium JJ, Minden MV, Saller-Hebert C, Eknoyan G, Martinez-Maldonado M. Acute treatment of hypercalcemia with furosemide. N Engl J Med 1970;283:836-40.
28. Purnell DC, VanJoerden JA. Management of symptomatic hypercalcemia and hypocalcemia. World J Surg 1982;6:706-9.
29. Silva OL, Becker KL. Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 1973;132:337-9.
30. Ralston SH, Dryburgh FJ, Cowan RA, Gardner MD, Jenkins AS, Boyle IT. Comparison of aminohydroxypropylidene diphosphonate, mithromycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia. Lancet 1985;2:907-10.
31. Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double blind comparison to calcitonin. Ann Intern Med 1988;108:669-74.
32. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980;93:269-72
33. Hosking DJ, Stone MD, Foote JW. Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy. Eur J Clin Pharmacol 1990;38:37-41.
34. Reitsma PH, Teitelbaum SL, Bijuoet OLM, Kahn AJ. Differential action of the bisphosphonates (3-amino-1-hydroxyprophylidene)-1,1-bisphosphonate (APD) and disodium dichloramethylidene bisphosphonate (CL2MDD) in rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982;70:927-33
35. Boonckamp PM, van der Wee-Pals LJA, van Wijk-van Leurep MLL, Thesing CN, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Mineral 1986;1:27-9.
36. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo Science 1969;165:1262-4.
37. Carano A, Teitlebaum SL, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-61.
38. O'Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994;69:914-7.
39. Ryzen E, Martodam RR, Troxell M, Benson A, Paterson A, Shepard K, et al. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med 1985;145:449-52.
40. Singer FR. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. Semin Oncol 1990;17(suppl 5):34-9.
41. Hasling C, Charles P, Mosekilde L. Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 1987:82(suppl 2A):51-4.
42. Jacobs TP, Gordon AC, Silverberg SJ, Shane E, Reich L. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. Am J Med 1987;82(suppl 2A):42-50.
43. Singer FR, Ritch PS, Lad TE, Ringernberg S, Schiller JH, Recker RR, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate: a controlled, multicenter study. Arch Intern Med 1991;151:471-6.
44. Gucalp R, Ritch P, Wiernik PH, Sarmon PR, Keller A, Richman SP. Comparative study of pamidronate disodium and etridronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-42.
45. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989;2:1180-2.
46. Warrell RP, Murphy WK, Schulman P, O'Dwey PJ, Heller G. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991;9:1467-75.
47. Flores JF, Rude RK, Chapman RA, Belani CP, Chang AY, Pritchard JD, et al. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer 1994;73:2527-34.
48. Sawyer N, Newstead C, Drummond A, Newland A, Cunningham J. One-shot high dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignanacy. Clin Lab Haematol 1989;11:179-84.
49. Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Mineral 1990;5:121-8.
50. Cantwell BMJ, Harris A. Effect of single high dose infusions of aminohydroxypropylidene diphosphate on hypercalcemia caused by cancer. Br Med J 1987;294:467-9.
51. Drug topics red book. Montvale, NJ: Medical Econcomics, 1994
52. Kristensen B, Ejlertsen B, Holmegaard SN, Krarup-Hansen A, Transbol Mouridsen H. Prednisolone in the treatment of severe malignant hypercalcemia in metastic breast cancer: a randomized study. J Intern Med 1992;232:237-45.
53. Warrell RP, Bookman RS, Coonley CJ, Isaacs M, Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984;73:1487-90.
54. Warrell RP Jr, Alcock NW, Bockman RS. Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol 1987;5:2928.
55. Newman RA, Brody AR, Krakoff IH. Gallium nitrate (NSC-15200) induced toxicity in the rat: a pharmacologic, histopathologic, and microanalytical investigation. Cancer 1979;44:1728-40.
56. Minkin C. Inhibition of parathyroid hormone stimulated bone resorption in vitro by antibiotic mimramycin. Calcif Tissue Res 1973;13:249-57.
57. Elias EG, Reynoso G, Mittelman A. Control of hypercalcemia with mithramycin. Ann Surg 1972;175:431-5.
58. Perlia CP, Gubisch NJ, Wolter J, Edelbeig D, Dederick MM, Taylor SG. Mithramycin treatment of hypercalcemia. Cancer 1970;25:389-94.